Lancashire and South Cumbria
Formulary
Formulary
4 Central nervous system
04-01-02 Anxiolytics
Anxiolytics should be used at the lowest possible dose for the shortest possible time.
Links
LSCMMG: Pregabalin- MHRA Drug Safety Update April 2016: Meprobamate: licence to be cancelled
- MHRA Drug Safety Update April 2022: Pregabalin (Lyrica): findings of safety study on risks during pregnancy
- MHRA Drug Safety Update Feb 2021: Pregabalin (Lyrica): reports of severe respiratory depression
- MHRA: Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression
- MHRA: Changes to drug driving law
- MHRA: Drugs and driving: blood concentration limits to be set for certain controlled drugs in a new legal offence
- MHRA: Pregabalin (Lyrica), gabapentin (Neurontin) and risk of abuse and dependence: new scheduling requirements from 1 April
- MHRA: Pregabalin (Lyrica): findings of safety study on risks during pregnancy
- MHRA: Pregabalin (Lyrica): reports of severe respiratory depression
- NICE CG113: Generalised anxiety disorder and panic disorder in adults: management
- NICE NG163: COVID-19 rapid guideline: managing symptoms (including at the end of life) in the community
- NICE NG215: Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults